https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=10009

Rilpivirine

Omeprazole

Contraindicated.

No pharmaceutical opinion available for this interaction.

Mechanism

Omeprazole by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of Rilpivirine.

Rilpivirine

Pharmacodynamic effects

Decreased clinical efficacy.

Risk of possible development of resistance to rilpivirine and other NNRTIs.

Recommendations

Avoid association.

Alternative solution(s)

–

Omeprazole

Pharmacodynamic effects

–

Recommendations

Contraindicated. Use alternative.

Alternative solution(s)

See rilpivirine + famotidine and rilpivirine + antacids.

Monitor

–

Tests

–

Pharmacokinetic parameters
Parameters
Reference number
# patients
HIV
Dose
Frequency
AUC
Cmax
Cmin
Rilpivirine
3555
16
-
150 mg *
QD
- 40 %
- 40 %
- 33 %
Omeprazole
3555
15
-
20 mg
QD
- 14%
- 14%
 
Comment

Ref #3555 : * The Interaction study has been performed with a dose higher than the recommended dose (25 mg QD) assessing the maximal effect on the coadministered drug.

Reference
  • 3555
    Crauwels HM, van Heeswijk RPG, Kestens D, Stevens M, Buelens A, et al. The pharmacokinetic interaction between omeprazole and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, 9-13 November 2008, abstract P239.
  • 2841
    Rilpivirine (Edurant), Janssen, Ontario, Canada, 4 mars 2019.
  • 2587
    Emtricitabine/Rilpivirine/Ténofovir DF (Complera), Gilead, Ontario, Canada, 17 octobre 2019.
  • 3441
    Dolutegravir/Rilpivirine (Juluca), ViiV Healthcare ULC, Quebec, Canada, 19 août 2021.
  • 3460
    Rilpivirine/Emtricitabine/Tenofovir alafenamide (Odefsey), Gilead Sciences, Ontario, Canada, 13 novembre 2019.